Salmonella typhi Ty21a bacterial ghost vector augments HIV-1 gp140 DNA vaccine-induced peripheral and mucosal antibody responses via TLR4 pathway

Vaccine

Volumn 30, Issue 39, 2012, Pages 5733-5739

  Wen, Jing ^a,e   Yang, Yi ^a   Zhao, Guangyu ^a   Tong, Shuang ^a   Yu, Hong ^a   Jin, Xia ^b   Du, Lanying ^c   Jiang, Shibo ^c,d   Kou, Zhihua ^a   Zhou, Yusen ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d FUDAN UNIVERSITY   (China)

^e SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Bacterial ghosts (BGs); DNA vaccine; HIV 1; Salmonella typhi Ty21a; TLR4 5

Indexed keywords

BACTERIAL GHOST; DNA VACCINE; DRUG CARRIER; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; TOLL LIKE RECEPTOR 4; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; INTESTINE MUCOSA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHI;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CELL LINE; FEMALE; HIV ANTIBODIES; IMMUNITY, MUCOSAL; INTERLEUKIN-10; MACROPHAGES; MICE; MICE, INBRED BALB C; SALMONELLA TYPHI; TOLL-LIKE RECEPTOR 4; VACCINES, DNA;

EID: 84864917961     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.008     Document Type: Article

References (33)

1. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blinded, randomized, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
2. Fitzgerald D.W., Janes H., Robertson M., Coombs R., Frank I., Gilbert P., et al. An Ad-5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from randomized placebo-controlled trial (The Step Study). J Infect Dis 2011, 203:765-772.
3. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
4. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005, 191:666-677.
5. Rerks-Ngarm S., Pitisuttihum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
6. Ortiz A.M., Klatt N.R., Li B., Yi Y., Tabb B., Hao X.P., et al. Depletion of CD4+ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J Clin Invest 2011, 121:4433-4445.
7. Walker B.D., Ahmed R., Plotkin S. Use both arms to bit HIV. Nat Med 2011, 17:1194-1195.
8. Mcmichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10:11-23.
9. Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464:217-223.
10. Jones D.H., Corris S., McDonalds S., Clegg J.C., Farrar G.H. Poly (dl-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997, 15:814-817.
11. Berzofsky J.A. A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Vaccine 2011, 10.1016/j.vaccine.2011.11.034.
12. Van Roey G.A., Arias M.A., Tregoning J.S., Rowe G., Shattock R.J. Thymic stromal lymphopoitin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol 2012, 42:353-363.
13. Vecino W.H., Morin P.M., Agha R., Jacobs W.R., Fennelly G.J. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HV. Immunol Lett 2002, 82:197-204.
14. Woo P.C.Y., Tsoi H.W., Leung H.C.H., Wong L.P., Wong S.S.Y., Chan E., et al. Enhancement by ampicillin of antibody responses induced by protein antigen and a DNA vaccine carried by live-attenuated Salmonella enterica serovar Typhi. Clin Diagn Lab Immunol 2000, 7:586-599.
15. Huang X., Liu L., Ren L., Qiu C., Wan Y., Xu J. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. Vaccine 2007, 25:8874-8884.
16. Huang X., Lu B., Yu W., Fang Q., Liu L., Zhuang K., et al. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS ONE 2009, 4:e4180.
17. Kibler K.V., Gomez C.E., Perdiguero B., Wong S., Huynh T., Holechek S., et al. Improved NYVAC-based vaccine vectors. PLoS ONE 2011, 6:e25674.
18. Garcia-Arriaza J., Najera J.L., Gomez C.E., Tewabe N., Sorzano C.O.S., Calandra T., et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-speicific T-cell responses. PLoS ONE 2011, 6:e24244.
19. Kudela P., Koller V.J., Lubitz W. Bacterial ghosts (BGs)-advanced antigen and drug delivery system. Vaccine 2010, 28:5760-5767.
20. Ebensen T., Pauker S., Link C., Kudela P., de Domenico C., Lubitz W., et al. Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol 2004, 172:6858-6865.
21. Kudela P., Paukner S., Mayr U.B., Cholujova D., Schwarczova Z., Sedlak J., et al. Bacterial ghosts as a novel advanced targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J Immunother 2005, 28:136-143.
22. Paukner S., Kudela P., Kohl G., Schlapp T., Friedrichs S., Lubitz W. DNA-loaded bacterial ghosts differently mediate reporter gene transfer and expression in macrophages. Mol Ther 2005, 11:215-223.
23. Barrell B.G., Air G.M., Hutchison C.A. Overlapping genes in bacteriophage PhiX174. Nature 1976, 264:34-41.
24. R/cI857 system for controlled gene E expression in Escherichia coli. FEMS Microbiol Lett 1999, 173:347-352.
25. Darji A., Guzman C.A., Gerstal B., Wachholz P., Timmis K.N., Wehland J., et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997, 91:765-775.
26. Vecino W.H., Morin P.M., Agha R., Jacobs W.R., Fennelly G.J. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunol Lett 2002, 82:197-204.
27. Baumler A.J., Tsolis R.M., Heffron F. The lpf fimbrial operon mediates adhesion of Salmonella typhimurium to murine Peyer's patches. Proc Natl Acad Sci USA 1996, 93:279-283.
28. Jones B.D., Ghori N., Falkow S. Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of Peyer's patches. J Exp Med 1994, 180:15-23.
29. Kou Z., Quinn M., Chen H., Rodrigo S.W.W., Rose R.C., Schlesinger J.J., et al. Monocytes, but not T or B Cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol 2008, 80:134-146.
30. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
31. Treanor J.J., Taylor D.N., Tussey L., Hay C., Nolan C., Fitzgerald T., et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010, 28:8268-8274.
32. Yu B., Yang M., Wong H.Y.B., Watt R.M., Song E., Zheng B.J., et al. A method to generate recombinant Salmonella typhi Ty21a strains expressing multiple heterologous genes using an improved recombineering strategy. Appl Microbiol Biotechnol 2011, 91:177-188.
33. Haslberger A.G., Kohl G., Felnerova D., Mayr U.B., Furst-Ladani S., Lubitz W. Activation, stimulation and uptake of bacteria ghosts in antigen presenting cells. J Biotechnol 2000, 83:57-66.